Information Provided By: 
Fly News Breaks for December 8, 2016
HZNP
Dec 8, 2016 | 10:14 EDT
Cowen analyst Ken Cacciatore, while acknowledging that the failure of Horizon Pharma's Actimmune in Friedreich ataxia is disappointing, said he never assumed success in this indication and had not factored FA in his model at all. Cacciatore believes Horizon shares are at a trough valuation and views the pullback as a "prescient entry point," he tells investors. He keeps an Outperform rating and $42 price target on Horizon Pharma.
News For HZNP From the Last 2 Days
There are no results for your query HZNP
